

Texas Vaccine Providers Webinar Highlights – January 5, 2022

Read below for topics covered or view the [full recording](#) for detailed information.

Opening Remarks

- DSHS’ Immunization Program will host a webinar on January 6, 2022, from 1:00 to 3:00 pm about updates surrounding the global and national impact of the current influenza season, current influenza disease rates in Texas, and strategies to increase influenza vaccination coverage levels in all populations. Register [here](#).

COVID-19 Vaccine Updates

- On January 3, 2022, the U.S. Food and Drug Administration (FDA) [amended the emergency use authorization \(EUA\)](#) for the Pfizer-BioNTech COVID-19 Vaccine to:
 - Expand the use of a **single booster dose to include use in individuals 12 through 15 years of age**. *Administration of a booster dose to individuals 12-15 years of age must await recommendations from the CDC.*
 - Shorten the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 Vaccine and a booster dose to at least **five months**. *Recommended by CDC on January 4, 2022.*
 - Allow for a **third primary series dose** for certain **immunocompromised children 5 through 11 years of age**. *Recommended by CDC on January 4, 2022.*
- The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) is meeting today, January 5, 2022, to issue clinical recommendations.
- Please exhaust your inventory of Pfizer COVID-19 purple cap vaccine before administering gray cap vaccine. You may begin ordering the gray cap vaccine once you have less than a one-month supply of purple cap vaccine remaining. To avoid errors, *please do not use Pfizer purple and gray cap vaccine products at the same time.*

Product Ordering Updates

- When placing **less than full pack size** orders of **Pfizer’s gray cap COVID-19 vaccine**, providers may now order **up to 102 doses**. Any order greater than 102 doses will be upgraded to a full pack size order of 300 doses. Review the updated [COVID-19 Vaccine Product Availability Chart](#) for details.

ImmTrac2: Reporting Pfizer COVID-19 Vaccine for Clients 12 Years and Older

- When reporting Pfizer’s purple cap COVID-19 vaccine administration in the Texas Immunization Registry, ImmTrac2, be sure to use the trade name “Pfizer COVID-19 Vaccine”; when reporting Pfizer’s gray cap COVID-19 vaccine administration, please use the trade name “COMIRNATY TS, 30mcg/0.3mL.”

Provider Resources:

- [COVID-19 Vaccine Management Resources \(training and support materials\)](#)
- [ImmTrac2 User Training Site](#)
- [ImmTrac2 Forms and Documents](#)
- [COVID-19 Vaccine Provider Enrollment Information](#)
- [CDC Clinical Considerations for or Use of mRNA COVID-19 Vaccines](#)
- DSHS Provider Help Desk: (833) 832-7068, 8 a.m. to 5 p.m., Monday through Friday; Email: COVID19VacEnroll@dshs.texas.gov

Live Q&A:

Below are a sample of the questions DSHS subject matter experts answered during the 1/5 webinar’s live Q&A session.

- If we do not waste any doses from vial of COVID-19 vaccine, do we need to report 0 doses as waste in VAOS?
- Are providers still able to administer J&J’s COVID-19 vaccine to eligible clients, despite the CDC’s clinical preference for individuals to receive an mRNA COVID-19 vaccine?
- When are COVID-19 boosters safe to administer to immunocompromised individuals, relative to the additional dose administered 28 days after their second dose?
- Can we administer a booster dose of COVID-19 vaccine to a client who received a primary series of a vaccine that is not authorized in the US?

